Completed PHASE3 INTERVENTIONAL NCT00122330

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients

Sponsor: Alexion Pharmaceuticals, Inc.

Interventions eculizumab

Updated 8 times since 2017 Last updated: Nov 30, 2006 Started: Oct 31, 2004 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00122330, this PHASE3 trial focuses on Hemoglobinuria, Paroxysmal and remains completed. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 8 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2023 — Jul 2024 [monthly]

Completed PHASE3
Apr 2023 — Dec 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Apr 2023 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexion Pharmaceuticals, Inc.

Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Basel, Switzerland , Belfast, United Kingdom , Bethesda, United States , Boston, United States , Brussels, Belgium , Cedex, France , Cleveland, United States , Duarte, United States , Dublin, Ireland and 31 more locations